Pharmaceutical giant Pfizer has announced it planned to submit a COVID-19 vaccine for children under the age of 5 to the Food and Drug Administration (FDA) of the United for emergency authorization.

9.5%. That’s how many adults aged 18 to 49 have a chronic condition that puts them at a high risk of severe RSV disease, according to Pfizer ... First RSV Vaccine For Kids-Given To Pregnant ...

Pfizer made $11.2 billion from sales of Comirnaty last year, while Moderna earned $6.7 billion in revenue from its vaccine Spikevax ... sending shares down 5% in extended trading.

Shares of the New York-based drugmaker, which have lost 11% of their value ... 3 million expected by analysts. Pfizer is fighting for market share for its RSV vaccine with a rival GSK (GSK.L ...

As Pfizer races to grow the respiratory ... Committee on Immunization Practices voted 11-1 in favor of recommending Abrysvo as a maternal vaccine. While Moderna moves off COVID, Spikevax posts ...

Meanwhile, both Pfizer-BioNTech and Moderna have suffered precipitous declines in COVID-19 vaccine revenue ... clocked in at $11.2 billion, falling short of the partners’ $13.5 billion goal ...

The first signs that H5N1 avian flu was starting to spread from person to person would trigger a race to produce massive ...

People age 5 and older are up to date after one Pfizer-BioNTech COVID ... COVID-19 vaccines for use in kids? For children ages 5 through 11, the FDA reviewed a vaccine study of more than 4,600 ...

That means that while Pfizer and Moderna vaccines use mRNA created in a lab that teaches people’s cells how to make copies of a spike protein that fights COVID-19, Novavax’s vaccine delivers ...

Vermont has the second lowest state fatality rate in the US (132.8 per 100K; Hawaii 104.3/100K). Mississippi (448.1/100K) and Oklahoma (445.3/100K) have the highest rates. The US average is 297.9/100K ...